Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Oramed Pharmaceuticals (ORMP) FCF Margin (2016 - 2025)

Oramed Pharmaceuticals filings provide 8 years of FCF Margin readings, the most recent being 176.1% for Q1 2025.

  • Quarterly FCF Margin changed N/A to 176.1% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 457.7% through Dec 2025, changed N/A year-over-year, with the annual reading at 457.7% for FY2025, N/A changed from the prior year.
  • FCF Margin hit 176.1% in Q1 2025 for Oramed Pharmaceuticals, up from 393.77% in the prior quarter.
  • Across five years, FCF Margin topped out at 176.1% in Q1 2025 and bottomed at 1377.18% in Q1 2022.
  • Average FCF Margin over 4 years is 721.63%, with a median of 645.57% recorded in 2023.
  • Peak annual rise in FCF Margin hit 86884bps in 2023, while the deepest fall reached 51411bps in 2023.
  • Oramed Pharmaceuticals' FCF Margin stood at 428.08% in 2021, then crashed by -116bps to 925.88% in 2022, then skyrocketed by 57bps to 393.77% in 2023, then soared by 55bps to 176.1% in 2025.
  • Per Business Quant, the three most recent readings for ORMP's FCF Margin are 176.1% (Q1 2025), 393.77% (Q2 2023), and 863.06% (Q1 2023).